# 1. Financial Performance ## A. Key Figures * **Total Income:** **₹180 Cr** Q3 FY26 (+19%) * International Patient Revenue: ₹703 Mn (+30%) * **OPD Pharmacy Revenue:** **₹465 Mn** (+30%) * EBITDA (ex-Noida): ₹2,814 Mn (+11%) · 25.4% margin * EBITDA (incl. Noida): ₹2,494 Mn · 21.8% margin * PAT: ₹950 million consolidated · ₹1,224 million adjusted PAT * **Net Cash Position:** **₹600 Cr** (Dec) ## B. Revenue Growth * **Broad-Based Momentum:** Strong double-digit revenue growth across all hospitals, supported by robust patient demand and improved operational efficiency. * **Specialty Revenue Strength:** International patient inflows and OPD pharmacy sales showed particularly strong momentum, reflecting enhanced service appeal and volume recovery. * **ALOS Volatility:** Short-term decline in average length of stay in mature units attributed to seasonal factors including Diwali and dengue outbreaks, not structural shifts. ## C. EBITDA Margins * **Core Margin Resilience:** Excluding Noida, core hospital EBITDA margins held steady, demonstrating operating leverage despite inflationary pressures. * **Noida Drag Expected:** Consolidated margin compression reflects planned losses at the new Noida facility, consistent with expansion phase economics. * **Cost Optimization Underway:** Material cost efficiencies in legacy units are yielding measurable improvements, signaling potential for margin reinvestment. * **Long-Term Margin View:** Management dismisses short-term margin swings (<100 bps) as noise; targets a sustainable 22–25% margin band post-COVID reset, with no expectation of sharp near-term jumps. ## D. Profit After Tax * **Statutory PAT Impact:** Reported profit after tax significantly affected by one-time labor code-related charge of **₹6 Cr** and Noida ramp-up costs. * **Adjusted Earnings Clarity:** Adjusted PAT provides a cleaner view of underlying operational performance, isolating non-recurring and growth-related expenses. ## E. Cash Flow & Balance Sheet * **Strong Liquidity Position:** Robust cash balance of **₹1,200 Cr** partially offset by **₹600 Cr** debt, resulting in a healthy net cash position of ₹600 Cr. --- # 2. Hospital Segment Performance ## A. Key Figures * Mature Hospitals Revenue: ₹7,020 Mn (+9%) · EBITDA: ₹1,675 Mn (+7%) · Margin: 23.9% * Developing Hospitals (inc. Noida): ₹3,994 Mn Revenue (+33%) · ₹836 Mn EBITDA · Margin: 20.9% * Noida (Q1): ₹343 Mn Revenue · (₹320 Mn) EBITDA loss * **ARPOB:** ₹56,853 (+8%) · **Inpatient Volumes:** +27% YoY ## B. Mature Hospitals * **Resilient Core Performance:** Mature hospitals delivered solid top-line and bottom-line growth, with management affirming underlying margins remain strong at **just under 24%** over nine months, within the expected 22–25% range. * **Margin Pressures Contained:** Slight reported margin dip attributed to higher employee costs and smaller, lower-margin facilities like Indore and Ranchi; however, their financial drag is **not material in absolute terms**. ## C. Developing Hospitals * **Efficient Scaling:** Developing hospitals (ex-Noida) achieved robust revenue growth and margin expansion from breakeven to **1%**, driven by operating leverage, bed expansion, and new specialties. * **Lucknow & Patna Momentum:** Both facilities delivered double-digit EBITDA growth, with **Lucknow improving margins by over 150 bps** on a 9M basis, reflecting successful scale-up. * **Volume-Driven Growth:** Strong 27% YoY inpatient volume growth and 8% ARPOB expansion underscore improving clinical traction and pricing power across the segment. ## D. Noida Ramp-Up Progress * **Ramp-Up on Track:** Noida completed its first full quarter with clinical and outreach progress; management confirms losses have likely peaked due to front-loaded hiring and commissioning costs. * **Accelerating Revenue Trajectory:** Revenue run rates improved in December–January, supporting expectations of loss reduction despite plans to add **over 200 beds**; focus remains on volumes, not occupancy targets. * **Structural Ramp-Up Challenge:** As a single-tower facility, Noida requires continuous construction vs. phased activation, contributing to teething issues, including **delayed Radiation Oncology commissioning** due to regulatory approvals. --- # 3. Capacity & Bed Expansion ## A. Key Figures * **Beds Added (9M FY26):** **537 beds** (+18% YoY) (**99 Patna** · **110 Ranchi** · **328 Noida**) * **Total Census Beds (Dec 2025):** **2,665 beds** (**Noida: 187** · **Gurgaon: 1,220** · **Lucknow: 604** · **Patna: 386**) * **Volume Growth (YoY):** **14% inpatient** · **20% outpatient** ## B. Bed Additions & Utilization * **Robust Volume Growth:** Strong double-digit expansion in both inpatient and outpatient volumes, reflecting effective bed absorption and rising demand across the network. * **Efficient Ramp-Up Strategy:** New beds added adjacent to operational zones with capex and fit-outs completed upfront; staffing scaled dynamically to match patient inflow. * **Optimization Focus:** Active initiatives to reduce average length of stay—currently **three days**—through daycare conversions and streamlined discharge, particularly in **Patna and Gurgaon**. * **Flexible Capacity Deployment:** Some floors held in reserve (“back pocket”) to align with occupancy trends, ensuring cost discipline during ramp-up. * **Clinical Expansion with Minimal Doctor Hiring:** Noida’s **200-bed expansion** to leverage existing senior clinical teams, adding mainly junior staff and support roles; new departments like **Obstetrics** introduced. ## C. Facility Construction Status * **Progress Across Pipeline:** Expansion advancing in **Guwahati**, **Mumbai**, **South Delhi**, and **Pitampura**, with key approvals secured or construction underway. * **Sustained Noida Development:** Infrastructure buildout continues progressively—without demobilization—deemed more efficient despite staggered bed activation. * **Minor Plan Adjustments:** Potential reallocation of **Patna’s remaining capacity** from beds to **procedure rooms** based on four-year operational insights; overall plan remains on track. --- # 4. Clinical & Service Expansion ## A. Key Figures * **ARPOB Impact:** **Higher realizations** and **lower ALOS** from robotics adoption driving disproportionate ARPOB upside vs. ARPP * **Service Expansion:** **Three or four robots** added, including orthopedic robots in Lucknow, enabling complex procedures * **Oncology Capacity:** **5th Radiation Oncology Machine** commissioned in Gurugram; departments in Lucknow and Patna fully resourced but not yet operational ## B. Specialty Program Growth * **Clinical Excellence Focus:** Continued emphasis on patient-centric care, clinical governance, and investment in expertise and infrastructure to strengthen tertiary and quaternary service delivery. ## C. Robotics & Technology Adoption * **JCI Milestone:** Medanta Lucknow achieved JCI accreditation in Jan-26, becoming the **first hospital in the region** to meet global standards in quality and safety. * **Technology-Driven Efficiency:** Robotics rollout enhancing procedural complexity and service depth, with positive implications for revenue per occupied bed. ## D. Oncology & Advanced Care * **Cancer Care Expansion:** Large-scale awareness campaign for Breast and Prostate Cancers over past six months aimed at early detection; treatment capacity boosted by new radiation machine in Gurugram. * **Operational Delay:** Despite full staffing and equipment, **Radiation Oncology and Nuclear Medicine** services remain non-operational at Lucknow and Patna facilities. * **Patient Mix Shift:** Rising **daycare volumes** in oncology, partially influenced by increased cases of Dengue and respiratory illnesses with longer stays. * **Realization Upside:** Balanced realization growth expected from expansion of **complex medical work**—including Transplants and robotic surgery—in newer centers. --- # 5. Pricing & Payer Mix ## A. Key Figures * **ARPOB:** **₹67,361** (+10% YoY) * **Occupancy:** **~59%** on expanded bed days (+7% occupied bed days) * **CGHS Impact:** **₹7–10 Cr** benefit over nine months; **high single-digit gross impact** ## B. ARPOB Trends * **Strong ARPOB Growth Driven by ALOS and Case Mix:** Recent double-digit ARPOB expansion reflects improved patient length of stay and favorable clinical mix, though management emphasizes its derived nature and volatility. * **Noida Outperforms Early Benchmarks:** Noida’s current ARPOB exceeds Gurgaon’s and matches Delhi’s, but remains preliminary due to nascent operations. * **Conservative Long-Term ARPOB Outlook:** Management projects **3%–7% annual ARPOB growth**, with recent double-digit gains not expected to persist; **single-digit realization growth** is the base-case trajectory. * **Pricing Discipline Across Markets:** Selective price increases in Gurgaon and Lucknow contrast with a hold in Patna, reflecting regional optimization rather than broad-based hikes. ## C. Insurance Contract Renewals * **Pricing Upside from Lapsed Contracts:** Renewals of agreements not updated for **two to three years** are unlocking tariff catch-up, with full impact expected by **June–September next year**. * **Renewals Reflect Multi-Year Tariff Rollforward:** New contracts based on **2025 tariffs** incorporate **approximately two years of price increases**, though final adjustments vary by insurer and unit. * **Noida Expanding Insurance Access Gradually:** Four to five major panels signed, but broader activation delayed to align with inclusive patient access goals, which may moderate near-term ARPOB. ## D. CGHS Rate Impact * **CGHS Revision Providing Measured Tailwind:** Implemented in **October**, the revision is driving a **high single-digit gross impact**, with benefits unfolding gradually over the next 6–12 months. * **Full Impact Still Pending:** Follow-on adjustments from institutional payers (e.g., railways) and **PPP partners in Bihar** remain in progress, delaying full realization. --- # 6. Talent & Operational Risks ## A. Clinician Hiring Challenges * **Non-Standardized Staffing Metrics:** Employee-to-bed ratios vary significantly by specialty and are not uniformly tracked or reported, limiting comparability across departments. * **Industry-Wide Talent Pressure:** Healthcare faces a sustained "war for talent," with intense competition in northern regions driven by high demand and rival hiring, particularly near established medical hubs. * **Brand-Driven Retention Strength:** Medanta maintains strong clinician loyalty, retaining **senior doctors in key locations like Gurgaon over 15 years**, supported by institutional reputation despite national talent scarcity. * **Cost Management Outlook:** Employee costs remain elevated due to active hiring, but management expects stabilization through operational efficiencies over time. ## B. Staffing for New Facilities * **Noida Hiring Largely Complete:** Approximately **220 doctors** have been onboarded, with core recruitment finished, though select specialties (e.g., Transplant, Pediatrics) remain under active hiring. * **Demand-Driven Scaling:** Most new infrastructure will integrate into existing operations without requiring new departments or major incremental staffing, except for specialized units. ## C. Regulatory Approvals Delay * **Ecosystem Interdependence:** Despite media-framed tensions, hospitals and insurers maintain a collaborative, interdependent relationship, with all key stakeholders—government, pharma, device makers—recognizing shared responsibility for system sustainability. --- # 7. Guidance & Outlook ## A. Key Figures * **5-Year CAPEX Plan:** **₹3,000 Cr** total, with major project spend back-ended over 2–3 years * **Additional Beds:** **496** brownfield expansion potential, including **193** in Lucknow, **81** in Patna, **222** in Noida * **EBITDA Breakeven:** Typically achieved at **40%–50%** occupancy in fixed-cost model ## B. CAPEX Plan * **CAPEX De-Risking:** Significant reduction in near-term spending with next year’s outlay below ₹500 Cr, as major investments shift to later stages of the five-year plan. * **Phased Investment Strategy:** Limited new unit spending due to early construction phase; focus remains on maintenance capex in mature facilities. ## C. Future Bed Ramp-Up * **High-Return Expansion:** Nearly **500 incremental beds** achievable via brownfield projects with minimal additional capex, enhancing scalability. * **Strategic Geographic Reach:** Expansion targets underserved markets including Patna and Noida, aligning with long-term regional penetration goals. ## D. Margin Expansion Expectations * **Margin Recovery Ahead:** Unit margin improvement expected in coming quarters as temporary pressures from employee and maintenance costs subside. * **Efficiency Gains Targeted:** Management aims to deliver **a couple of hundred bps** of system-wide efficiency gains despite volatility, with no anticipated structural margin headwinds. * **Noida Ramp-Up Confidence:** While no formal EBITDA guidance provided, management affirms Noida is on track with **strong positive momentum**; current losses may be near peak.